BOTHELL, Wash.--(BUSINESS WIRE)--Plexera Biosciences LLC, a wholly owned subsidiary of Lumera Corporation (NASDAQ:LMRA), announced today that it has signed an Early Access Agreement with an undisclosed leading therapeutic antibody company as its first participant in the company’s Early Access Program.
